HomeCompareSAUHY vs PFE

SAUHY vs PFE: Dividend Comparison 2026

SAUHY yields 2.03% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SAUHY wins by $158.6K in total portfolio value
10 years
SAUHY
SAUHY
● Live price
2.03%
Share price
$10.32
Annual div
$0.21
5Y div CAGR
57.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$208.2K
Annual income
$102,257.93
Full SAUHY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SAUHY vs PFE

📍 SAUHY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSAUHYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SAUHY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SAUHY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SAUHY
Annual income on $10K today (after 15% tax)
$172.97/yr
After 10yr DRIP, annual income (after tax)
$86,919.24/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SAUHY beats the other by $64,599.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SAUHY + PFE for your $10,000?

SAUHY: 50%PFE: 50%
100% PFE50/50100% SAUHY
Portfolio after 10yr
$128.9K
Annual income
$64,258.32/yr
Blended yield
49.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SAUHY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
8.9
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SAUHY buys
0
PFE buys
0
No recent congressional trades found for SAUHY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSAUHYPFE
Forward yield2.03%6.13%
Annual dividend / share$0.21$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR57.4%13.2%
Portfolio after 10y$208.2K$49.6K
Annual income after 10y$102,257.93$26,258.71
Total dividends collected$177.1K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: SAUHY vs PFE ($10,000, DRIP)

YearSAUHY PortfolioSAUHY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,020$320.29$9,153$693.39+$1.9KSAUHY
2$12,311$519.23$8,593$849.25+$3.7KSAUHY
3$14,026$853.25$8,336$1,066.78+$5.7KSAUHY
4$16,438$1,430.01$8,437$1,384.80+$8.0KSAUHY
5$20,054$2,465.31$9,013$1,875.40+$11.0KSAUHY
6$25,882$4,424.30$10,306$2,680.72+$15.6KSAUHY
7$36,093$8,399.71$12,820$4,101.38+$23.3KSAUHY
8$55,851$17,231.25$17,673$6,826.70+$38.2KSAUHY
9$98,984$39,223.20$27,543$12,591.86+$71.4KSAUHY
10$208,171$102,257.93$49,560$26,258.71+$158.6KSAUHY

SAUHY vs PFE: Complete Analysis 2026

SAUHYStock

Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. The company offers dental implant systems for tissue and bone level; titanium, titanium alloy, ceramic, and mini dental implant systems; and guided and non-guided surgical instruments, as well as implant-borne prosthetics. It provides ceramic healing and screw retained abutments; intraoral scanning solutions; 3D printers; milling machines; and prevention products. In addition, it offers biomaterials, bone substitutes, membranes, biologics, and soft tissue management and oral healing products; digital solutions for dental labs, dentists, and centralized milling centers, as well as materials, third party systems, and guided surgery; surgical instruments comprising surgical and modular cassettes, guided instruments, implant maintenance products, bone block fixation sets, bonerings, titanium pin sets, and other cassettes; and edentulous, pro arch fixed, prosthetic, and mini implant solutions for edentulous patients. Further, it provides esthetic restorations that include ceramic implant monotypes, ceramic implants, abutments, biologics, and other solutions; and Emdogain for wound healing. Further, it offers systems Clear Correct aligners; and training and education services to its customers. The company provides its products to general dentists, specialists, and dental technicians and laboratories, as well as corporate customers, such as distributors, hospitals, universities, and dental service organizations in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

Full SAUHY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SAUHY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SAUHY vs SCHDSAUHY vs JEPISAUHY vs OSAUHY vs KOSAUHY vs MAINSAUHY vs JNJSAUHY vs MRKSAUHY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.